ENO2 and cancer: Additionally, we considered treatment information (e.g., ultraacute reperfusion therapy, intravenous thrombolysis, bridging therapy, endovascular treatment), complications (e.g., hyperlipidemia, alcohol abuse, active cancer, prestroke disability, respiratory infection), laboratory indicators (e.g., fasting blood glucose, glycated hemoglobin, C‐reactive protein, creatinine, neutrophil count, monocyte count, PCT, neuron‐specific enolase, blood calcium), and time variables (e.g., time of onset, hospital arrival time, reperfusion time).